Company
Founded in 2017, Newmanbrain company was born with the mission of making unbiased cognitive assessment available for mass screening. We wanted to build an accessible and easy to use system that clinicians and patients would “thrive” to use on a daily basis.
After years of research and long days and nights of hard work, we obtained our final stable fNIRS prototype with an optimized design and functionality. In parallel to this hardware optimization, we started to develop a software platform with the purpose of collecting the data from the fNIRS device, depict it in real-time graphs and, finally, perform an AI-powered data analytics pipeline to provide clinicians with a report explaining the patient’s cognitive performance during the task.
Our system allows us to address one of the biggest problems in science today: to correlate the activity of diverse areas of the brain with mental functions (thoughts, emotions, sensations and motor functions). This is a new change of paradigm that will change how professionals evaluate, diagnose and treat different cognitive-related conditions.
Our History
Our History
Our idea could change the whole mental care paradigm.
Literature review about fNIRS.
Starting I+D UMH Physiology department - feasibility of using fNIRS technology.
With 2 new PhDs and 2 engineers that incorporated to the Physiology department.
With the first voluntary patients in the lab.
A spin-off of Miguel Hernandez University.
Assisted to multiple congresses: 2nd International Congress of Psychobiology. 17th National Congress Spanish Neuroscience Society (SENC). I International Congress of Investigation and Intervention.
First increase in share capital.
Framework agreement between UMH, the Institute of Neurosciences and Newmanbrain.
IN4 Bankia award "Best Startup".
Memorandum of Understanding (Spanish Hub for Innovation) signed.
First investment round Friends & Family.
Presentation of our fNIRS system in the 27th Healthcare Forum Barcelona 2020.
EU Seal of Excellence.
ENISA participatory loan (Spanish government).
Seed capital with UK-based and US-based fund.
Started CE mark process - IIA medical device classification.
- Successfully ended a ruled Clinical Trial.
- Closed bridge round 400k € (convertible notes).
- Full IP protection by patents.
- 3 publications in high impact journals.
- Clinical Trial publication.
- Demostration in operational enviroments.
- CE Mark pending approval.
Come visit us
Our headquarters are located in Alicante (Spain).
